Toumi M, Zard J, Duvillard R, Jommi C
University Claude-Bernard Lyon-I, 11, rue Guillaume-Paradin, 69372 Lyon, cedex 08, France.
Ann Pharm Fr. 2013 Sep;71(5):302-25. doi: 10.1016/j.pharma.2013.08.005. Epub 2013 Sep 5.
Market Access Agreements (MAA) for drugs have emerged in response to the need to control health expenditures, as well as to the uncertainty about the true benefit of a drug. It is possible to group MAA in two types of agreements: financial agreements and outcome-based agreements. MAA is a growing trend and is shifting towards conditional access. However, the willingness to use these contracts and their implementation differ across countries, and some are still resistant to put them in place. The MAA challenges to overcome encompass the complexity of the schemes, the administrative burden and the difficulty of evaluating MAA. It is likely that these agreements might experience further evolution in the future to become a faster pathway for therapeutic innovations, at a fair price.
药品市场准入协议（MAA）的出现是为了应对控制医疗支出的需求以及药品真正效益的不确定性。MAA可以分为两类协议：财务协议和基于结果的协议。MAA是一种不断发展的趋势，正朝着有条件准入转变。然而，各国使用这些合同的意愿及其实施情况各不相同，一些国家仍抵制实施这些协议。需要克服的MAA挑战包括方案的复杂性、行政负担以及评估MAA的困难。这些协议未来可能会进一步演变，以合理价格成为治疗创新的更快途径。
